Relief Therapeutics announces positive results for PKU treatment
Biopharmaceutical company Relief Therapeutics has announced positive results from its bioequivalence study of RLF-OD032 for the treatment of phenylketonuria (PKU).
The study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN Powder, the reference listed drug, as defined by the US Food and Drug Administration (FDA). RLF-OD032 was well tolerated, with no serious adverse events reported.
The randomised, open-label, two-way crossover study compared the pharmacokinetics of RLF-OD032 (administered without water) and the reference product (administered with water, as per its labelling) under fed conditions. The results are based on a pre-database lock analysis (soft lock) and are expected to be confirmed following final data verification.
RLF-OD032 offers a novel approach to PKU management by addressing key limitations of current sapropterin therapies, which must be mixed with large volumes of water. As a ready-to-use, highly concentrated liquid, RLF-OD032 can be administered directly, without water, offering a portable, low-volume, and patient-friendly alternative.
RLF-OD032, which offers up to 100-fold reduction in dose volume, simplifies daily treatment and is expected to improve adherence, optimise outcomes, and enhance quality of life for children and adults living with PKU.
The challenges of living with PKU
Phenylketonuria (PKU) is a genetic disorder caused by a deficiency of the enzyme needed to break down phenylalanine (Phe), leading to a toxic buildup of Phe from the consumption of foods containing protein or aspartame. Individuals with PKU lack the ability to metabolise Phe, which is present in many foods. Without treatment, PKU can cause severe neurological and developmental issues.
The standard treatment involves a lifelong phenylalanine-restricted diet supplemented with amino acid-based, phenylalanine-free medical foods to prevent protein deficiency and optimise metabolic control. However, this diet is highly restrictive and often creates barriers to social interaction, limiting compliance and increasing the risk of poor disease management.
Relief Therapeutics plans to proceed with final data verification and completion of CMC activities in preparation for submission of a 505(b)(2) New Drug Application (NDA). The NDA is expected to be filed in early 2026, seeking US marketing approval for the treatment of PKU, and will be subject to a 10-month FDA review under the 505(b)(2) pathway.
Bruno Quinney, Content Team, DDW
